Key Documents

View All Documentation

1136002

USP

Clindamycin hydrochloride

Name: Clindamycin hydrochloride
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

Clindamycin hydrochloride monohydrate, (7S)-7-Chloro-7-deoxylincomycin hydrochloride monohydrate

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₈H₃₃ClN₂O₅S · HCl · H₂O

CAS Number:

58207-19-5

Molecular Weight:

479.46

MDL number:

MFCD06411091

UNSPSC Code:

41116107

NACRES:

NA.24

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

grade

pharmaceutical primary standard

API family

clindamycin

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

S([C@H]1O[C@@H]([C@@H]([C@@H]([C@H]1O)O)O)[C@H](NC(=O)[C@H]2[N+H](C[C@@H](C2)CCC)C)[C@@H](Cl)C)C.[Cl-].O

InChI

1S/C18H33ClN2O5S.ClH.H2O/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4;;/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25);1H;1H2/t9-,10+,11-,12+,13-,14+,15+,16+,18+;;/m0../s1

InChI key

KWMXKEGEOADCEQ-WNNJHRBUSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Materials for Pharma QC

Pharmacopeia & Metrological Institute Standards

General description

Clindamycin is a lincosamide antibiotic which is considered as a semisynthetic derivative of lincomycin. It is mainly used as an antimicrobial agent.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Clindamycin hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

Storage Class

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

涉药品监管产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Efficacy of clindamycin hydrochloride capsules for the treatment of deep pyoderma due to Staphylococcus intermedius infection in dogs.

D W Scott et al.

The Canadian veterinary journal = La revue veterinaire canadienne, 39(12), 753-756 (1998-12-23)

Clindamycin hydrochloride capsules (11 mg/kg body weight, q24 h) were administered orally to 20 dogs with deep staphylococcal pyoderma. Response to therapy was excellent in 100% of the dogs. Duration of therapy varied from 21 to 91 d, with an

Increased neutrophil extracellular trap-mediated Staphylococcus aureus clearance through inhibition of nuclease activity by clindamycin and immunoglobulin.

Katrin Schilcher et al.

The Journal of infectious diseases, 210(3), 473-482 (2014-02-15)

The Gram-positive human pathogen Staphylococcus aureus causes a variety of human diseases such as skin infections, pneumonia, and endocarditis. The micrococcal nuclease Nuc1 is one of the major S. aureus virulence factors and allows the bacterium to avoid neutrophil extracellular

Cutaneous botryomycosis diagnosed long after an arm injury.

Norma Mechow et al.

Journal of the American Academy of Dermatology, 71(4), e155-e156 (2014-09-16)

Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents.

D Gonzalez et al.

Clinical pharmacology and therapeutics, 96(4), 429-437 (2014-06-21)

Clindamycin is commonly prescribed to treat children with skin and skin-structure infections (including those caused by community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA)), yet little is known about its pharmacokinetics (PK) across pediatric age groups. A population PK analysis was performed in

The early use of appropriate prophylactic antibiotics in susceptible women for the prevention of preterm birth of infectious etiology.

Jan Stener Joergensen et al.

Expert opinion on pharmacotherapy, 15(15), 2173-2191 (2014-09-10)

Preterm birth is the major cause of perinatal mortality and morbidity in high-income countries. The etiology of preterm birth is multifactorial but there is overwhelming evidence to implicate infection as a major cause. Abnormal genital tract flora in early pregnancy

View All Related Papers

Global Trade Item Number

SKU	GTIN
1136002-200MG	04061838701312

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service